Month: January 2025

AleAnna Celebrates Milestone As It Contributes To Europe’s Access To Secure And Sustainable Energy And Leads In The Transition To Low Carbon Energy SolutionsAleAnna utilizes cutting-edge reservoir characterization technologies and possesses over 140,000 acres of 3D seismic data to optimize reservoir performance and unlock Italy’s natural gas reserves. AleAnna owns significant holdings spanning over 2.7 million acres, including Italy’s largest onshore natural gas discovery in two decades. AleAnna’s RNG portfolio includes over 100 projects, representing $1.1 billion in investment potential, driving renewable energy and sustainability in Europe. AleAnna’s management team and board of directors is exceptionally qualified, boasting a proven track record of world-class execution and leadership excellence.DALLAS and ROME, Jan. 23,...

– U.S. FDA 510(k) filing of next-generation Novasight system targeted for H2 2025 with U.S. commercial launch planned for early 2026– Evolving medical guidelines position next-generation Novasight system as new imaging standard in interventional cardiology– Multiple non-dilutive opportunities being pursued to fund growth TORONTO, Jan. 23, 2025 (GLOBE NEWSWIRE) — To our Shareholders, As we enter 2025, I’m encouraged by our recent progress and the favorable strategic landscape. Having completed our go-public transaction and raised concurrent financing of US$7.7 million, Conavi is well positioned to set a new imaging standard for the most common procedures in interventional cardiology. The case for our Novasight platform has never been stronger. With the new European interventional cardiology guidelines strongly...

– Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease (AD) – – Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement – – Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025; Selects 25mg QD oral as a dose that fully engages desired pharmacology – WATERTOWN, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) — Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of AD....

Separately: Secures $234K Plasma Torch Contract for Methane Conversion MONTREAL, Jan. 23, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (http://pyrogenesis.com) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY), a high-tech company that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, announces the granting of European Patent EP 2 686 100 B1, titled “Steam Plasma Arc Hydrolysis of Ozone Depleting Substances”. This granted patent covers PyroGenesis’ cutting-edge process for the highly efficient destruction of ozone depleting substances, such as used refrigerants from end-of-life cooling apparatus. This European patent complements PyroGenesis’ U.S. Patent No. 11,116,069, granted in September...

Key Highlights:Revenue and Gross Profit Growth with Reduced Losses: GURU achieved a 3.3% increase in net revenue to $30.2 million in 2024, while gross profit grew by 8.4% to $16.7 million, reflecting improved margins. Net loss decreased significantly by 21.3% to $9.4 million, underscoring the impact of disciplined cost management and operational efficiencies. Strong U.S. Momentum in Online and Retail Channels: GURU experienced significant growth of 61.6% in the U.S. in 2024. Margin Expansion: Gross margin improved to 55.3% from 52.7% in 2023, highlighting ongoing cost optimization and effective pricing strategies. Solid Financial Position: Maintained a solid financial position with $25.5 million in cash, $10 million of unused credit facilities and no debt. Growing Consumer Engagement: Successfully sampled over 450,000 units through Costco...

FORT WORTH, Texas, Jan. 23, 2025 (GLOBE NEWSWIRE) — American Airlines Group Inc. (NASDAQ: AAL) today reported its fourth-quarter and full-year 2024 financial results, including:Record fourth-quarter revenue of $13.7 billion and record full-year revenue of $54.2 billion Fourth-quarter and full-year GAAP net income of $590 million and $846 million, or $0.84 and $1.24 per diluted share, respectively Excluding net special items1, fourth-quarter and full-year net income of $609 million and $1.4 billion, or $0.86 and $1.96 per diluted share, respectively Generated $4 billion in full-year operating cash flow and record full-year free cash flow2 of $2.2 billion Announced an exclusive 10-year co-branded credit card partnership with Citi, which is expected to unlock even more value for AAdvantage® co-branded and Citi-branded cardmembers Achieved...

MONTREAL, Jan. 23, 2025 (GLOBE NEWSWIRE) — Troilus Gold Corp. (TSX: TLG; OTCQX: CHXMF; FRA: CM5R) (“Troilus” or the “Company”), reports that it has expanded its engineering team with three key appointments, further strengthening its capabilities as the Troilus Project (“the Project”) advances into the development and construction phase. The Company is pleased to welcome Mr. Denis Rivard as Executive Vice President, Projects and Chris Sharpe as Vice President of Technical Services, effective February 1, 2025. In addition, Jérôme Girard will be joining the team as Process Manager for the Troilus Project, effective February 10, 2025. These additions underscore Troilus’ commitment to assembling a best-in-class team to advance one of the largest undeveloped gold-copper deposits in Canada, bolstering the Company’s technical expertise...

CAMBRIDGE, Mass., Jan. 23, 2025 (GLOBE NEWSWIRE) — Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the company will encore data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease in an oral presentation at the 2025 Tandem Meetings | Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and Center for International Blood and Marrow Transplant Research (CIBMTR) taking place February 12 – 15, 2025, in Honolulu, Hawaii.  Data from seven patients treated with investigational base-editing therapy BEAM-101 were previously presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2024. Treatment with BEAM-101 demonstrated...

Investor webinar scheduled Tuesday, January 28, 2025, at 8:00 AM EST MIAMI, Jan. 23, 2025 (GLOBE NEWSWIRE) — SAB BIO (Nasdaq: SABS), (“SAB” or the “Company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), announced today that the Company will host a Research and Development webinar on January 28, 2025 to discuss the topline data for Phase 1 clinical trial for its lead candidate, SAB-142. The webinar will feature presentations from SAB BIO’s management team and T1D Key Opinion Leader (KOL) Michael Haller, MD, the division chief of the Pediatric Endocrinology Division at the University of Florida and Silverstein Family Eminent Scholar Chair in Pediatric Endocrinology. Webinar...

MONTREAL, Jan. 23, 2025 (GLOBE NEWSWIRE) — Aya Gold & Silver Inc. (TSX: AYA; OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce that it has reached and surpassed the nameplate milling capacity at its 100% owned Zgounder Mine located in the Kingdom of Morocco. The new plant began processing ore on November 4th, 2024. The first silver pour was achieved on November 27th, with commercial production reached on December 29th, less than two months after the new plant began processing the first ore. Over a consecutive 30-day period ending on January 20th, 2025, the new plant processed a total of 65,990 tonnes (“t”) of ore, an average of 2,200 tonnes per day (“tpd”), and equivalent to 110% of nameplate capacity. Processing rates averaged 96 tonnes per hour (“tph”), at 96% availability. Silver recovery was 85%. Between...